Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Nov 2024 – Affilogic is presenting at the next I4ID congress : Perring Jacquot is presenting latest data on anti-influenza Nanofitin®-based therapeutics. Pulmonary delivered anti-influenza Nanofitins® exert very promising efficacy results in-vivo in mice.
Nov 2024 – Affilogic CSO Mathieu Cinier is presenting at PEGS Europe 2025: Mathieu will present new approaches using Nanofitins® to treat infectious disease. Nanofitin® alternative scaffold generation platform allows for the generation of therapeutic candidates of high neutralisation potential in roughly 100 days, and can be amenable to local treatment in the case of pulmonary diseases.
Affilogic will attend next BiotechShowcase in San-Francisco – USA
Jan 13-15, 2025
Affilogic presenting at 8th I4ID in Lyon – France
Nov 27-28, 2024
Affilogic will attend next BIO EUROPE in Stockholm – Sweden
Nov 4-6, 2024
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read MoreAffilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read MoreAffilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More